Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.

Journal of virological methods - 1 Dec 2016

Heger Eva, Theis Alexandra Andrée, Remmel Klaus, Walter Hauke, Pironti Alejandro, Knops Elena, Di Cristanziano Veronica, Jensen Björn, Esser Stefan, Kaiser Rolf, Lübke Nadine

Abstract excerpt

Phenotypic resistance analysis is an indispensable method for determination of HIV-1 resistance and cross-resistance to novel drug compounds. Since integrase inhibitors are essential components of recent antiretroviral combination therapies, phenotypic resistance data, in conjunction with the corresponding genotypes, are needed for improving rules-based and data-driven tools for resistance prediction, such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 3-Ring
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Quinolones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 27737783
DOI: 10.1016/j.jviromet.2016.10.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.PMID 27737783Read ↗

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.Semantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.Semantic proximity Read ↗

Systematic determination of in vitro phenotypic resistance to HIV-1 integrase strand transfer inhibitors from clinical samplesSemantic proximity Read ↗

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.Semantic proximity Read ↗

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical IsolatesSemantic proximity Read ↗

Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.Semantic proximity Read ↗

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.Semantic proximity Read ↗

Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.Semantic proximity Read ↗

Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data.Semantic proximity Read ↗

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.